Literature DB >> 6840159

Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine.

O Banzet, J N Colin, M Thibonnier, E Singlas, J M Alexandre, P Corvol.   

Abstract

A tablet formulation of nifedipine was given to 8 hospitalized hypertensive men, W.H.O. stage I or II, mean age 45 years. After an initial placebo test, nifedipine 20, 40 or 60 mg was given in random order at 72-h intervals, in a single administration crossover study. The placebo and the active drug were given at 8 a.m. Blood pressure and heart rate were measured twice by the same observer, every 20 min from 7 to 8 a.m., and then hourly until 8 p.m., first in recumbency and again after 1 min of standing upright. Plasma nifedipine was assayed in samples taken hourly from 8 a.m. to noon, every 2 h from noon to 8 p.m., and 24 and 48 h after drug administration. All 3 doses significantly lowered blood pressure; the fall during recumbency was significantly larger (-18%) and lasted longer (12 h) after 60 mg than after 20 mg (-11% and 7 h). All 3 doses caused a similar increase in heart rate (+29 to +38%), which reached its maximum after 2 h and lasted for 5 h. The maximum plasma concentration and the area under the plasma concentration--time curve were dose-dependent despite large inter-subject variation. Absorption, bioavailability and elimination were linear between the 20 and 60 mg doses. Plasma nifedipine levels were strongly correlated with the concomitant decrease in mean arterial blood pressure (r = 0.61, p less than 0.001). Four patients experienced mild side effects (headaches, flushes, drowsiness or weakness). This tablet form of nifedipine has a potent antihypertensive action which lasts longer than that of the capsule presentation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840159     DOI: 10.1007/bf00613808

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Comparison of acute effects of nifedipine in normotensive and hypertensive man.

Authors:  O Lederballe Pedersen; N J Christensen; K D Rämsch
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

2.  Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection.

Authors:  P Jakobsen; O Lederballe Pedersen; E Mikkelsen
Journal:  J Chromatogr       Date:  1979-01-01

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

Review 4.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

5.  Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension.

Authors:  M Thibonnier; F Bonnet; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

6.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

7.  Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker).

Authors:  J Menard; X Bertagna; P T N'Guyen; P Degoulet; P Corvol
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

8.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

9.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03

10.  Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen; N J Christensen; H J Kornerup; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

View more
  13 in total

1.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.

Authors:  K S Woo; C O Pun
Journal:  West J Med       Date:  1990-02

4.  Simultaneous study of the pharmacokinetics of intravenous and oral nicardipine using a stable isotope.

Authors:  M Guerret; G Cheymol; M Hubert; C Julien-Larose; D Lavene
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.

Authors:  V Challenor; D G Waller; B S Gruchy; A G Renwick; C F George; E T McMurdo; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

6.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Slow release nifedipine plus atenolol in chronic stable angina pectoris.

Authors:  V F Challenor; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

8.  Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: a randomised crossover study.

Authors:  F P Cappuccio; N D Markandu; F A Tucker; G A MacGregor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 10.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.